- New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
- Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer
Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236
San Francisco, CA (UroToday.com) -- Bayer will announce data from the Company’s evolving oncology portfolio at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15, 2020 in San Francisco, California. The presentations across the latest research for Bayer’s marketed and pipeline therapies highlight the company’s ongoing commitment to exploring the potential of its therapies across different indications and treatment settings.
New data on the effect of Nubeqa® (darolutamide) on cerebral blood flow compared to enzalutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) will be presented. Nubeqa, an androgen receptor inhibitor (ARi) jointly developed by Bayer and Orion Corporation, is approved in the U.S., Japan and Brazil, and recently received a positive CHMP opinion in the European Union (EU).
The research presented from Bayer’s prostate cancer portfolio will also include several presentations that feature real-world and combination studies with Xofigo® (radium Ra 223 dichloride) in men with certain types of prostate cancer. Among these is the first presentation of investigational data from a randomized Phase II study of sipuleucel-T (SipT) with or without Xofigo in men with asymptomatic metastatic castration-resistant prostate cancer (mCRPC).
Notable presentations at ASCO GU 2020 are listed below:
Darolutamide
- Analysis of cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers
- Abstract: 326, Poster Session A: Prostate Cancer; Board M10
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer
- Abstract: TPS384, Trials in Progress Poster Session A: Prostate Cancer; Board Q4
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
Radium Ra 223 Dichloride (radium-223)
- Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC) – Investigator initiated research (IIR)
- Abstract: 130, Poster Session A: Prostate Cancer; Board F10
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
- Abstract: 32, Poster Session A: Prostate Cancer; Board A20
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): a retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
- Abstract: 50, Poster Session A: Prostate Cancer; Board B16
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Variance in symptom assessment between patient and caregiver: a prospective study of patients staged as metastatic prostate cancer — an interim analysis – IIR
- Abstract: 56, Poster Session A: Prostate Cancer; Board B22
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints – IIR
- Abstract: 125, Poster Session A: Prostate Cancer; Board F5
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- PRINT: Prostate Cancer Intensive, Non-Cross Reactive Therapy for CRPC — Early Observations of Efficacy – IIR
- Abstract: 89, Poster Session A: Prostate Cancer; Board D13
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- The National Radium-223 Dichloride Audit Group: data from patients in United Kingdom oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride – IIR
- Abstract: 59, Poster Session A: Prostate Cancer; Board C3
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Results of the ADRRAD Trial of pelvic IMRT plus radium-223 in men with mHSPC metastatic to bone – IIR
- Abstract: 136, Poster Session A: Prostate Cancer; Board F16
- February 13, 11:30am – 1:00pm, 5:30 – 6:30pm (PST)
- Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration resistant prostate cancer (mCRPC): a U.S. tertiary oncology center analysis
- Abstract: 223, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B1
- February 14, 12:15 – 1:45pm, 5:15 – 6:15pm (PST)
- Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: A Japanese post-marketing study (PMS)
- Abstract: 236, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B14
- February 14, 12:15 – 1:45pm, 5:15 – 6:15pm (PST)